Key result
Combined immunomodulatory therapy linked to stabilization or improvement of giant coronary aneurysms in pediatric MIS-C.
Why the study?
Giant coronary aneurysms are infrequent but serious cardiac manifestations in MIS-C associated with SARS-CoV-2 infection, with limited case descriptions and treatment data.
Case Report (n=3)
May support multi-agent therapy including biologics for MIS-C giant aneurysms; leaves open need for prospective trials.
Multisystem inflammatory syndrome in children (MIS-C) can cause a myriad of cardiac manifestations, including coronary dilation and aneurysms; giant aneurysms are infrequent. We describe 3patients with giant coronary aneurysms associated with MIS-C, including the youngest case reported to date, treated with intravenous immunoglobulin, corticosteroids, and biologic agents. (Level of Difficulty: Intermediate.)
No takes yet. Share an insight, caveat, or question.
Villacis-Nunez et al. (2021) conducted a case report in Multisystem inflammatory syndrome in children (MIS-C) with giant coronary aneurysms (n=3). Intravenous immunoglobulin (IVIG), corticosteroids, and biologic agents was evaluated. Three children with MIS-C and giant coronary aneurysms demonstrated partial improvement or stabilization of coronary dimensions following treatment with IVIG, corticosteroids, and biologic agents.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: